Abstract P22: Decoding ecDNA in Breast Cancer: From Patient-Derived Models to AI-Enhanced Clinical Detection

Abstract Extrachromosomal DNA (ecDNA) drives oncogene amplification and therapy resistance across cancers, yet its role in breast cancer requires more comprehensive mechanistic understanding. We developed comprehensive ecDNA breast cancer models including patient-derived cell lines, xenografts (PDX), and organoids (PDO) from tumor specimens, characterizing them through whole-genome sequencing to map ecDNA profiles and copy number variation/structural variant landscapes, revealing distinct ecDNA patterns within our cohort. Analysis of TCGA public datasets comparing expression profiles between ecDNA-positive and ecDNA-negative groups demonstrated that ecDNA-positive breast cancers significantly downregulate immune-activating pathways while upregulating mitosis and cell-cycle pathways, indicating ecDNA's dual impact on immune evasion and enhanced replicative capacity. These findings establish ecDNA as a critical driver of breast cancer progression through coordinated regulation of immune suppression and cellular proliferation mechanisms. To democratise ecDNA detection in breast cancer, we validate the use of AI-based image processing to predict ecDNA status from routine H&E histopathology slides. Our pilot study achieved 82.4% accuracy and 60% precision. The promising results obtained highlights the need for enhanced model fine-tuning specifically for breast cancer and local population characteristics. This integrated experimental-computational framework establishes ecDNA as a therapeutically targetable driver in breast cancer while pointing to possible implementations of ecDNA testing in clinical practice. Citation Format: Zexi Guo, Jeremy Wee Kiat Ng, Kenneth Chun Cheng Bong, Vikneswari Rajasegaran, Jessica Sook Ting Kok, Elizabeth Chun Yong Lee, Hui Xin Lau, Jabed Iqbal, Jason Yongsheng Chan, Bin Tean Teh, Timothy Kwang Yong Tay, Yoon Sim Yap, Kah Suan Lim, Tira Jing Ying Tan. Decoding ecDNA in Breast Cancer: From Patient-Derived Models to AI-Enhanced Clinical Detection [abstract]. In: Proceedings of Frontiers in Cancer Science 2025; 2025 Nov 5-7; Singapore. Philadelphia (PA): AACR; Cancer Res 2026;86(13_Suppl):Abstract nr P22.

Authors

Institutions

Publication Details

Journal
Cancer Research
Published
2026-07-02
DOI
https://doi.org/10.1158/1538-7445.fcs2025-p22
Primary Topic
Cancer Genomics and Diagnostics
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

Abstract P22: Decoding ecDNA in Breast Cancer: From Patient-Derived Models to AI-Enhanced Clinical Detection

Vikneswari Rajasegaran, Elizabeth Chun Yong Lee, Timothy Kwang Yong Tay, Kah Suan Lim et al.
Cancer Research
Cancer Genomics and Diagnostics
article

Abstract P22: Decoding ecDNA in Breast Cancer: From Patient-Derived Models to AI-Enhanced Clinical Detection

Vikneswari Rajasegaran, Elizabeth Chun Yong Lee, Timothy Kwang Yong Tay, Kah Suan Lim, Bin Tean Teh, Jason Yongsheng Chan, Jessica Sook Ting Kok, Jeremy Wee Kiat Ng, Zexi Guo, Hui Xin Lau, Yoon Sim Yap, Jabed Iqbal, Tira Jing Ying Tan, Kenneth Chun Cheng Bong
article en

Abstract

Abstract Extrachromosomal DNA (ecDNA) drives oncogene amplification and therapy resistance across cancers, yet its role in breast cancer requires more comprehensive mechanistic understanding. We developed comprehensive ecDNA breast cancer models including patient-derived cell lines, xenografts (PDX), and organoids (PDO) from tumor specimens, characterizing them through whole-genome sequencing to map ecDNA profiles and copy number variation/structural variant landscapes, revealing distinct ecDNA patterns within our cohort. Analysis of TCGA public datasets comparing expression profiles between ecDNA-positive and ecDNA-negative groups demonstrated that ecDNA-positive breast cancers significantly downregulate immune-activating pathways while upregulating mitosis and cell-cycle pathways, indicating ecDNA's dual impact on immune evasion and enhanced replicative capacity. These findings establish ecDNA as a critical driver of breast cancer progression through coordinated regulation of immune suppression and cellular proliferation mechanisms. To democratise ecDNA detection in breast cancer, we validate the use of AI-based image processing to predict ecDNA status from routine H&E histopathology slides. Our pilot study achieved 82.4% accuracy and 60% precision. The promising results obtained highlights the need for enhanced model fine-tuning specifically for breast cancer and local population characteristics. This integrated experimental-computational framework establishes ecDNA as a therapeutically targetable driver in breast cancer while pointing to possible implementations of ecDNA testing in clinical practice. Citation Format: Zexi Guo, Jeremy Wee Kiat Ng, Kenneth Chun Cheng Bong, Vikneswari Rajasegaran, Jessica Sook Ting Kok, Elizabeth Chun Yong Lee, Hui Xin Lau, Jabed Iqbal, Jason Yongsheng Chan, Bin Tean Teh, Timothy Kwang Yong Tay, Yoon Sim Yap, Kah Suan Lim, Tira Jing Ying Tan. Decoding ecDNA in Breast Cancer: From Patient-Derived Models to AI-Enhanced Clinical Detection [abstract]. In: Proceedings of Frontiers in Cancer Science 2025; 2025 Nov 5-7; Singapore. Philadelphia (PA): AACR; Cancer Res 2026;86(13_Suppl):Abstract nr P22.

Cancer ResearchVol. 86(13_Supplement)
Singapore General Hospital (SG), Duke-NUS Medical School (SG), National Cancer Centre Singapore (SG)
Good health and well-being
Openalex Percentile: Top 9%
Cancer Genomics and Diagnostics
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.